following a full submission
ranibizumab (Lucentis®) is accepted for use within NHS Scotland.
Indication under review: Treatment for visual impairment due to choroidal neovascularisation secondary to pathologic myopia in adults.
In patients with choroidal neovascularisation secondary to pathologic myopia, ranibizumab intravitreal injection was associated with a significant improvement in visual acuity of 8.4 Early Treatment Diabetic Retinopathy Study letters at three months compared with photodynamic therapy.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of ranibizumab. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice144KB (PDF)
Medicine details
- Medicine name:
- ranibizumab (Lucentis)
- SMC ID:
- 907/13
- Indication:
- Treatment for visual impairment due to choroidal neovascularisation secondary to pathologic myopia in adults.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Eye
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 November 2013